GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Corona Remedies Ltd

Corona Remedies Q2 FY27 Standalone Net Profit at Rs. 60.18 Crores

RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 30 Oct 2026, 06:28 PM IST  ·  BSE ID: 35aa322d-0527-4313-be1f-e814e07a6893
View Original BSE Filing (PDF)
💡
In Simple Terms
Corona Remedies' Board approved its latest financial results for the quarter and half-year ending September 30, 2026, showing increased revenue and profit.
🤖 AI Summary
  • Board approved standalone and consolidated financial results for Q2 and Half Year ended September 30, 2026.
  • Standalone revenue from operations for Q2 FY27 was Rs. 441.17 Crores, compared to Rs. 361.13 Crores in Q2 FY26.
  • Standalone Net Profit after tax for Q2 FY27 stood at Rs. 60.18 Crores, against Rs. 52.15 Crores in Q2 FY26.
  • Half-year standalone revenue from operations was Rs. 863.60 Crores, with net profit after tax of Rs. 120.28 Crores.
  • The financial results include an Independent Auditor's Review Report by Walker Chandiok & Co LLP.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Q2 FY27 Standalone Revenue from Operations
Rs. 441.17 Crores
22.16%
Q2 FY27 Standalone Net Profit after Tax
Rs. 60.18 Crores
15.40%
Half Year FY27 Standalone Revenue from Operations
Rs. 863.60 Crores
21.90%
Half Year FY27 Standalone Net Profit after Tax
Rs. 120.28 Crores
22.06%
Q2 FY27 Basic EPS
Rs. 9.84
15.36%
🏢 How This Affects the Company
📈
Business Impact
The company reported an increase in standalone revenue from operations, indicating sales growth in Q2 FY27 and for the first half of FY27 compared to prior periods.
💰
Financial Impact
Standalone net profit after tax increased to Rs. 60.18 Crores for Q2 FY27 and Rs. 120.28 Crores for the half-year, reflecting improved earnings.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders based on this filing.
👤
Who Is Affected
All shareholders are indirectly affected as the financial results provide an update on the company's operational and financial performance for Q2 FY27 and the half-year.
🔍
Management Signal
The Board's approval and disclosure of financial results indicate ongoing compliance with regulatory requirements and transparency regarding company performance.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Q3 FY27 financial results — assess sustained revenue and profit growth.
Company's next press release — monitor updates on operational developments.
Changes in borrowings — observe management of short and long-term debt.
LOW RISK The filing reports positive financial results with no new immediate risks identified.
💡 Investor Takeaway
Corona Remedies reported standalone revenue from operations of Rs. 441.17 Crores for Q2 FY27, up 22.16% from Rs. 361.13 Crores in Q2 FY26. Net Profit after tax reached Rs. 60.18 Crores for Q2 FY27, a 15.40% increase from Rs. 52.15 Crores in Q2 FY26. Half-year standalone revenue was Rs. 863.60 Crores, with net profit at Rs. 120.28 Crores.
⚖️ Strengths & Concerns

✅ Positives

  • Standalone revenue from operations increased to Rs. 441.17 Crores in Q2 FY27 from Rs. 361.13 Crores in Q2 FY26, representing a 22.16% YoY growth.
  • Standalone Net Profit after tax rose to Rs. 60.18 Crores in Q2 FY27 from Rs. 52.15 Crores in Q2 FY26, a 15.40% YoY increase.

⚠️ Concerns

  • Other financial assets under non-current assets decreased to Rs. 50.86 Crores as of September 30, 2026, from Rs. 129.87 Crores as of March 31, 2026.
  • Cash and cash equivalents decreased to Rs. 1.58 Crores as of September 30, 2026, from Rs. 1.83 Crores as of March 31, 2026.
📅 Company Track Record
Corona Remedies recently listed via an IPO on December 15, 2025. In Q1 FY27, the company reported revenue up 21.9% to Rs. 422.4 Crores and PAT up 30.1%. For FY26, revenue was up 17.3% to Rs. 1,403.2 Crores and PAT up 33.4%, indicating a consistent growth trend in its recent public history.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Corona Remedies' standalone net profit in Q2 FY27?
Corona Remedies' standalone net profit after tax for the second quarter ended September 30, 2026, was Rs. 60.18 Crores.
What was Corona Remedies' standalone revenue from operations in Q2 FY27?
The standalone revenue from operations for Corona Remedies in Q2 FY27 was Rs. 441.17 Crores, increasing from Rs. 361.13 Crores in Q2 FY26.
What is the Basic Earnings Per Share (EPS) for Corona Remedies in Q2 FY27?
The Basic Earnings Per Share (EPS) for Corona Remedies in Q2 FY27 was Rs. 9.84, compared to Rs. 8.53 in Q2 FY26.
What were Corona Remedies' standalone financial results for the half year ended September 30, 2026?
For the half year ended September 30, 2026, Corona Remedies reported standalone revenue from operations of Rs. 863.60 Crores and a net profit after tax of Rs. 120.28 Crores.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.